Chronic Hepatitis B
Conditions
Brief summary
To evaluate the efficacy and safety of HRS9950 tablets in chronic hepatitis B patients who are virologically suppressed on nucleoside or nucleotide analogues (NAs).
Interventions
DRUGHRS9950 tablets
HRS9950 tablets, oral, once a week, low dose
DRUGHRS9950 placebo tablets
HRS9950 placebo tablets, oral, once a week.
Sponsors
Chengdu Suncadia Medicine Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Meet the body mass index standard among 18.0 to 30 kg/m2;； 2. Chronic hepatitis B defined as HBV infection documented for at least 6 months prior to screening; 3. Virologically suppressed on nucleoside or nucleotide analogues treatment with HBV DNA below the lower limit of quantitation; 4. On commercially available NAs monotherapy for at least 24 weeks before randomization, and the dosing regimen remained unchanged for at least 12 weeks before randomization; 5. Need to take effective contraceptive measures； 6. Volunteer to sign an informed consent.
Exclusion criteria
1. History of cirrhosis or clinical evidence of hepatic decompensation, confirmed or suspected liver cancer, with other liver diseases other than chronic hepatitis B that may affect the evaluation of the study; 2. With autoimmune disease; 3. With poorly-controlled diabetes, thyroid disease requiring clinical intervention, clinically significant thyroid dysfunction, neurological or psychiatric disorder, severe lung disease, chronic renal disease or retinopathy; 4. History of solid organ transplantation or hematopoietic stem cell transplantation; 5. Poorly-controlled hypertension, clinically significant and unstable or uncontrolled severe cardiovascular and cerebrovascular diseases; 6. Malignant tumors were diagnosed within 5 years prior to randomization； 7. Infection requiring intervention within 4 weeks prior to randomization; 8. Major trauma or major surgery within the 12 weeks prior to randomization, or surgical plans or other treatment during the study period which the investigators determined may influence the evaluation of the study results; 9. Laboratory tests during the screening period were obviously abnormal; 10. Prolonged ECG QTc interval (male \> 450ms, female \> 470ms) or other clinically significant abnormal results that may pose significant safety risks to subjects during the screening period; 11. History of drug use, alcohol or drug abuse in the 12 months prior to randomization; 12. Participated in clinical study of other drugs (received experimental drugs); 13. Pregnant or nursing women; 14. Allergic to a drug ingredient or component; 15. Other reasons for ineligibility as judged by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in mean log10 serum hepatitis B surface antigen levels from baseline to week 24 | Week 24 |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of subjects with at least one log10 decline from baseline in serum hepatitis B surface antigen | Pre-specified time points up to 48 weeks |
| Proportion of subjects with serum hepatitis B surface antigen loss | Pre-specified time points up to 48 weeks |
| Proportion of subjects with serum hepatitis B surface antigen seroconversion | Pre-specified time points up to 48 weeks |
| Changes from baseline in mean log10 serum hepatitis B surface antigen levels | Pre-specified time points up to 48 weeks |
| Proportion of subjects with serum hepatitis B e-antigen seroconversion | Pre-specified time points up to 48 weeks |
| Proportion of subjects with virologic breakthrough | Pre-specified time points up to 48 weeks |
| Proportion of subjects with drug resistance | Pre-specified time points up to 48 weeks |
| Proportion of subjects with hepatitis B e-antigen loss | Pre-specified time points up to 48 weeks |
Countries
China
Outcome results
None listed